C3i (Centre for Commercialisation of Cancer Immunotherapy) is a full-service CDMO offering services that including process development, GMP manufacturing, QC analytical development, biomarker development, immune monitoring, and CRO services. Based in Montreal, Canada, C3i is solely committed to developing and manufacturing novel, nontoxic immunotherapies. It is a one-stop-shop CDMO supporting the development of cancer treatments using cell and gene therapy.